What Is the Optimal Interval Between Chemoradiation and Esophagectomy?

Seminars in Thoracic and Cardiovascular Surgery

Volumn 24, Issue 2, 2012, Pages 87-89

  Martin, Linda W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Esophageal cancer; Esophagectomy; Multimodality therapy; Outcomes; Radiation

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROPYRIMIDINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; LONG TERM SURVIVAL; MINIMALLY INVASIVE SURGERY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CHEMORADIOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HEALTH STATUS; HUMANS; NEOADJUVANT THERAPY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865361764     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2012.06.001     Document Type: Article

References (10)

1. Ajani J, Barthel J, Bentrem D, et al: NCCN clinical practice guidelines in oncology: Esophageal and esophagogastric junction tumors (excluding the proximal 5 cm of the stomach). Version 2.2011. J Natl Compr Canc Netw. National Comprehensive Cancer Network.
2. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
3. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
4. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007, 8:226-234.
5. Courrech Staal E.F., Aleman B.M., Boot H., et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010, 97:1482-1496.
6. Kim J.Y., Correa A.M., Vaporciyan A.A., et al. Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg 2012, 93:207-212.
7. Ruol A., Rizzetto C., Castoro C., et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: Does delayed surgery have an impact on outcome?. Ann Surg 2010, 252:788-796.
8. Francois Y., Nemoz C.J., Baulieux J., et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999, 17:2396.
9. Dolinsky C.M., Mahmoud N.N., Mick R., et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol 2007, 96:207-212.
10. Tran C.L., Udani S., Holt A., et al. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg 2006, 192:873-877.